 Vor Biopharma Inc NASDAQ: VOR has collaborated with Janssen Biotech Inc, a unit of Johnson Johnson NYSE: JNJ. Under the terms of the collaboration, Vor Biopharma will investigate the combination of Vors engineered hematopoietic stem cell eHSC platform with one of Janssens bi-specific antibodies for acute myeloid leukemia AML. 